Toxicity antagonists in cancer therapy

Current Opinion in Oncology

Volumn 9, Issue 6, 1997, Pages 569-578

  Trotti, Andy ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIPHOSTINE; ANTIINFLAMMATORY AGENT; CAPTOPRIL; CISPLATIN; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; EPIRUBICIN; ESSENTIAL FATTY ACID; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYALURONIC ACID; IFOSFAMIDE; KERATINOCYTE GROWTH FACTOR; LISOFYLLINE; MESNA; MISOPROSTOL; NITROXIDE DERIVATIVE; PENTOXIFYLLINE; RAZOXANE; SUPEROXIDE DISMUTASE; TEMPOL; THIOL DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ALOPECIA; CANCER PATIENT; CANCER THERAPY; CARDIOMYOPATHY; CHRONIC TOXICITY; CLINICAL TRIAL; HEART PROTECTION; HELIUM NEON LASER; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; NEPHROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION INJURY; REVIEW;

EID: 0030779155     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199711000-00013     Document Type: Review

References (80)

1. National Cancer Institute, Cancer Therapy Evaluation Program, Bethesda, Maryland.
2. Coleman N, Bump E, Kramer R: Chemical modifiers of cancer treatment. J Clin Oncol 1988, 6:709-733.
3. Schuchter LM, Luginbuhl WE: The current status of toxicity protectants in cancer therapy. Semin Oncol 1992, 19:742-751.
4. Schuchter LM: Current role of protective agents in cancer treatment. Oncol 1997, 11:505-516. An excellent review of cytoprotectors and toxicity antagonists, with a focus on amifostine.
5. Klatersky J: Supportive care in cancer. Current Opinion in Oncology 1997, 9:313.
6. Peters LJ: Radiation therapy tolerance limits for one or for all?-Janeway Lecture. Cancer 1996, 77:2379-2385.
7. Delanian S, Baillet F, Huart J, Lefaix J, Moulard C, Housset M: Successful treatment of radiation-induced fibrosis using liposomal Cu/Zn superoxide dismutase: clinical trial. Radiotherapy and Oncology 1994, 32:12-20.
8. Mustoe TA, Porras-Reyes BH: Modulation of wound healing response in chronic irradiated tissues. Clinics in Plastic Surgery 1993, 20:465-472.
9. Hall EJ: Radiobiology for the Radiologist, edn 4. Philadelphia: JB Lippincott; 1994.
10. Rubin P, Casarett GW: Clinical radiation pathology. Philadelphia: W.B. Saunders; 1968.
11. Withers HR, Peters LJ, Kogelnik HD: The pathobiology of late effects of irradiation. In Radiation Biology in Cancer Research. Edited by Meyn RE, Withers HR. New York: Raven Press; 1980:439-448.
12. Maity A, Kao GD, Muschel RJ, McKenna WG: Potential molecular targets for manipulating the radiation response. Int J Rad Onc Biol Phys 1997, 37:639-653.
13. Rubin P, Johnston C, Williams J, McDonald S, Finkelstein J: A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Rad Onc Biol Phys 1995, 33:99-100. Among the first reports to characterize the post-treatment effects as a sequence of inflammatory cascades. Well supported by laboratory data.
14. Martin M, Lefaix J-L, Pinton P, Crechet F, DaBuron F: Temporal modulation of TGF-Beta-1 and Beta-Actin Gene Expression in Pig Skin and Muscular Fibrosis after Ionizing Radiation. Rad Res 1993, 134:63-70.
15. Randall K, Coggle JE: Long-term expression of transforming growth factor TGF Beta 1 in mouse skin after localized beta-irradiation. Int J Rad Biol Phys 1996, 70:351-60.
16. Anscher MS, Kong FM, Murase T, Jirtle RL: Short communication: normal tissue injury after cancer therapy is a local response exacerbated by an endocrine effect of TGFβ. Br J Radiol 1995, 68:331-333. Circulating levels of TGFβ appear to correlate with late effects supporting its role in exacerbating radiation late effects.
17. Wu L, Siddiqui A, Morris DE, Cox DA, Roth SI, Mustoe TA: Transforming growth factor B3 (TGFB3) accelerates wound healing without alteration of scar prominence. Arch Surg 1997, 132:753-760.
18. Bernstein EF, Harisiadis L, Salomon G, et al:. Transforming growth factor-β improves healing of radiation-impaired wounds. Soc Invest Dermatol 1991, 97:430-434.
19. Moreland LW, Baumgartner SW, Schiff MH, et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc Fusion protein. N Engl J Med 1997, 337:141-147. A good example of new products from the biotechnology industry which may open new horizons in modulation of normal tissue response. TNFα is induced by radiation and some types of chemotherapy.
20. Mollman JE, Glover DJ, Hogan WM, et al.: Cisplatin neuropathy: Risk factors, prognosis and protection by WR-2721. Cancer 1988, 61:2192-2195.
21. Al-Sarraf M, Fletcher WS, Oishi N, et al.: Cisplatin hydration with and without mannitol in refractory disseminated malignant melanoma: A Southwest Oncology Group Study. Cancer Treat Rep 1982, 66:31-35.
22. Glover D, Glick J, Weiler C, et al.: WR-2721 protects against the hematologic toxicity of cyclophosphamide: A controlled phase II trial. J Clin Oncol 1986, 4:584-588.
23. Kemp G, Rose P, Lurain J, et al.: Amifostine pretreatment for protection against cyclophosphamide-and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer. J Clin Ocol 1996, 14:2101-2112. The seminal study of amifostine that led to approval for use in ovarian platinum-containing chemotherapy regimens.
24. Mehta M, Larson MM, Pharo L, Larson, ML, Storer B, Schiller JL: Phase II Clinical Trial of Amifostine, Cisplatin, vinblastine (ACV) and radiation therapy (RT) for unresectable stage III nonsmall cell lung cancer (NSCLC). ASCO 1995.
25. Buntzel J, Kuttner K, Russell L, Oster W, et al.: Selective cytoprotection by amifostine in the treatment of head and neck cancer with simultaneous radiochemotherapy. Proceedings of ASCO 1997, Vol. 16, Abstract 1400.
26. Perdereau B, Campana F, Vilcoq JR, et al.: Superoxyde dismutase (Cu/Zn) en application cutanee dans le traitement des fibroses radioinduites. Bull Cancer 1994, 81:659-669.
27. Benyahia B, Campana F, Perdereau, et al.: The effects of superoxide dismutase topical treatment on human skin radiofibrosis: a pathological study. Breast 1995:1-7.
28. Chopra M, Scott N, McMurray J, et al.: Captopril: a free radical scavenger. Br J Clin Pharm 1989, 27:396-399.
29. Roberts NA, Robinson PA: Copper chelates of antirheumatic and antiinflammatory agents: their superoxide dismutase-like activity and stability. Br J Rheumatol 1985, 24:128-136.
30. Nguyen L, Ward WF, Ts'ao Ch, Molteni A: Captopril inhibits proliferation of human lung fibroblasts in culture: A potential antifibrotic mechanism. Proc Soc Exp Biol Med 1994, 205:80-84.
31. Moulder JE, Robbins MEC, Cohen EP, et al.: Pharmacologic modification of radiation-induced late normal tissue injury. In Radiation Therapy. Edited by BB Mittal, JA Purdy, KK Ang. Kluwer Academic Publishers, 1977, in press. An excellent and indepth review of the principles of normal tissue modulation, with a focus on Captopril.
32. Ward WF, Lin PP, Wong PS, et al.: Radiation pneumonitis in rats and its modification by the angiotensin-converting enzyme inhibitor captopril evaluated by high-resolution computed tomography. Radiat Res 1993, 135:81-87.
33. Ward WF, Kim YT, Molteni A, Solliday NH: Radiation-induced pulmonary endothelial dysfunction in rats: Modification by an inhibitor of angiotensin converting enzyme. Int J Radiat Oncol Biol Phys 1988, 15:135-140.
34. Ward WF, Molteni A, Ts_ao CH, Hinz JM: Captopril reduces collagen and mast cell accumulation in irradiated rat lung. Int J Radiat Oncol Biol Phys 1990, 19:1405-1409.
35. Mitchell JB, Samuni A, Krishna CM, et al.: Biologically active metal-independent superoxide dismutase mimics. Biochemistry 1990, 29:2802-2807.
36. Goffman T, Cuscela D, Glass J, et al.: Topical application of nitroxide protects radiation-induced alopecia in guinea pigs. Int J Rad Onc Biol Phys 1992, 22:803-806.
37. Cuscela D, Coffin D, Lupton GP, et al.: Protection from radiation-induced alopecia with topical application of nitroxides: fractionated studies. Cancer J Sci Am 1996, 2(5):273-278.
38. Green MD, Alderton P, Sobol MM, et al.: ICRF-187 (ADR-529) cardioprotection against anthracycline-induced cardiotoxicity: clinical and preclinical studies. In New Drugs, Concepts, and Results in Cancer Chemotherapy. Edited by Muggia FM. Kluwer Academic Publishers, Boston, Massachusetts; 1992:101-117.
39. Hasinoff BB: The iron (III) and copper (II) complexes of adriamycin promote the hydrolysis of the cardioprotective agent ICRF-187 [(+)-1,2-bis (3,5-dioxopiperazinyl-1-yl)propane). Agents Actions 1990, 29:374-381.
40. Speyer JL, Green MD, Zelenluch-Jacquotte A, et al.: ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992, 10:117-127.
41. Hellmann K: Dexrazoxane and doxorubicin cardiotoxicity [abstract]. 7th International Symposium on Supportive Care in Cancer, September 20-23, 1995, Luxembourg.
42. Wexler LH, Andrich MP, Venzon D, et al.: Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Onc 1996, 14(2):362-372.
43. Venturini M, Michelotti A, Del Mastro L, et al.: Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Onc 1996, 14:3112-20.
44. Schoenike SE, Dana WJ: Ifosfamide and mesna. Clin Pharm 1990, 9:179-191.
45. Ganser A, Karthaus M: Clinical use of hematopoietic growth factors. Current Opinion in Oncology 1996, 8:265-269.
46. Trillet-Lenoir V, Green J, Manegold C, et al.: Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993, 29A:319-324.
47. Gabrilove J, Jakubowski A, Scher H, et al.: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium. N Engl J Med 1988, 318:1414-1422.
48. Crawford J, Ozer H, Stoller R, et al.: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991, 325:164-170.
49. Sonis ST, Lindquist I, Van Vugt A, et al.: Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor beta 3. Cancer Res 1994, 54:1135-1138.
50. Werner S, Peters KG, Longaker MT, et al.: Large induction of keratinocyte growth factor expression in the dermis during wound healing. Proc Natl Acad Sci U S A 1992, 89:6896-6900. Laboratory study of growth factor inhibition of epithelial toxicity.
51. Marchese C, Rubin J, Ron D, et al.: Human keratinocyte growth factor activity on proliferation and differentiation of human keratinocytes: differentiation response distinguishes KGF from EGF family. J Cell Physiol 1990, 144:326-332.
52. Housley RM, Morris CF, Boyle B, et al.: Keratinocyte growth factor induced proliferation of hepatocytes and epithelial cells throughout the rat gastrointestinal tract. J Clin Invest 1994, 94:1764-1777
53. Absher M, Baldor L, Kelly J: A rapid calorimetric bioassay for transforming growth factor-(TGF-β) using a microwell plate reader. J Immunol Meth 1991, 138:301-303.
54. Horrobin DF: Nutritional and medical importance of gamma-linolenic acid. Prog Lipid Res 1992, 31:163-194.
55. Cole AT, Slater K, Sokal M, et al.: Elevated rectal leukotriene B4, thromboxane B2 and prostaglandin E2 levels in patients having pelvic radiotherapy. In Eicosanoids and other bioactive lipids in cancer, inflammation and radiation injury. Edited by Nigam S, Honn KV, et al. Boston: Kluwer Academic Publishers; 1993:771-773.
56. Hopewell JW, Gerard JM, Van Den Aardweg JMJ, et al.: Amelioration of both early and late radiation-induced damage to pig skin by essential fatty acids. Int J Rad Oncol Biol Phys 1994, 30:1119-1125.
57. Liguori V, Guillemin C, Pesce GF, et al.: Double-blind, randomized clinical study comparing hyaluronic acid cream to placebo in patients treated with radiotherapy. Radiotherapy and Oncology 1997, 42:155-161.
58. Braverman B, McCarthy RJ, Ivankovich AD, et al.: Effect of helium-neons and infrared laser irradiation on wound healing in rabbits. Laser Surg Med 1989, 9:50-58.
59. Bosatra M, Jucci A, Olliaro P: In vitro fibroblast and dermis fibroblast activation by laser irradiation at low energy. Dermatologica 1984, 168:157-162.
60. Labbe R, Skogerboe K, Davis H, et al.: Laser photobioactivation mechanisms: in vitro studies using ascorbic uptake and hydroxyproline formation as biochemical markers of irradiation response. Laser Surg Med 1990, 10:201-207.
61. Barasch A, Peterson DE, Tanzer JM, et al.: Helium-Neon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients. Cancer 1995, 76:2550-2556.
62. Cowen D, Tardieu C, Schubert M, et al.: Low energy helium-neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: results of a double blind randomized trial. Int J Rad Oncol Biol Phys 1997, 38(4):697-703.
63. Foote RL, Loprinzi CL, Frank AR, et al.: Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis. J Clin Oncol 1994, 12:2630-2633.
64. Sullivan GW, Carper HT, Novick WJ Jr, et al.: Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline. Infect Immun 1988, 56:1722-1729.
65. Hussey DH, Friedland JL: Second report of a pilot study of pentoxifylline in the treatment of late radiation necrosis. Workshop Proceedings of Pentoxifylline Leukocyte Cytokines: Potential Therapeutic Uses". Scottsdale, Arizona; March 8-10, 1991, (In Press).
66. Futran ND, Trotti A, Gwede C: Pentoxifylline in the Treatment of Radiation-Related Soft Tissue Injury: Preliminary Observations. Laryngoscope 1997, 107:391-395.
67. Cornelison TL, Naydich BO, Hicks JE, et al.: Trial of pentoxifylline in patients with functional disability caused by radiation-induced advanced regional fibrosis. Society of Gynecologic Oncologists 28th Annual Meeting, March 22-26, 1997.
68. Tsan MF: Superoxide dismutase and pulmonary oxygen toxicity. Pro Sol Exp Bio Med 1997, 214:107-113.
69. Bianco JA, Appelbaum FR, Nemunaitis J, et al.: Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 1991, 78:1205-1211.
70. Clift RA, Bianco JA, Appelbaum FR, et al.: A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation. Blood 1993, 82:2025-2030.
71. Attal M, Huguet F, Rubie H, et al.: Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: a prospective, randomized trial. Blood 1993, 82:732-736.
72. Stockschlader M, Kalhs P, Peters S, et al.: Intravenous pentoxifylline failed to prevent transplant-related toxicities in allogenic bone marrow transplant recipients. Bone Marrow Transplant 1993, 12:357-362.
73. van der Jagt RH, Pari G, McDiarmid SA, et al.: Effect of pentoxifylline on regimen related toxicity in patients undergoing allogeneic or autologous bone marrow transplantation. Bone Marrow Transplant 1994, 13:203-207.
74. Kalhs P, Lechner K, Stockschlader M, et al.: Pentoxifylline did not prevent transplant-related toxicity in 31 consecutive allogeneic bone marrow transplant recipients. Blood 1992, 80:2683-2684.
75. Lee SH, Slattery JT: Cytochrome P450 isozymes involved in lisofylline metabolism to pentoxifylline in human liver microsomes. Drug Metabolism and Disposition 1997; in press.
76. Clarke E, Rice GC, Weeks RS, et al.: Lisofylline inhibits transforming growth factor release and enhances trilineage hematopoietic recovery after 5-fluorouracil treatment in mice. Cancer Res 1996, 56:105-112.
77. Rice G, Rosen J, Weeks R, et al.: CT1501R selectively inhibits induced inflammatory monokines in human whole blood ex vivo. Shock 1994, 1:254-66.
78. List A, Maziarz R, Stiff P, et al.: Lisofylline (LSF) reduces infection rate and improves survival in pts undergoing allogeneic bone marrow transplantation (BMT): results of a randomized, placebo-controlled trial [abstract]. Blood 1996, 88:459a.
79. Milas L, Hanson WR: Eicosanoids and Radiation. European Journal of Cancer 1995, 31A(10):1580-1585.
80. Hanson QR, Marks JE, Reddy SP, et al.: Protection from radiation-induced oral mucositis by misoprostol prostaglandin E1 analog: a placebo controlled double blind clinical trial. Am J Therapeutics 1995, 2:1-8.